Noncoding RNAs as a novel approach to target retinopathy of prematurity

Bibliographic Details
Title:	Noncoding RNAs as a novel approach to target retinopathy of prematurity
Authors:	Hyunjong Kim, Jaesub Kim, Juhee Ryu
Source:	Frontiers in Pharmacology, Vol 13 (2022)
Publisher Information:	Frontiers Media S.A., 2022.
Publication Year:	2022
Collection:	LCC:Therapeutics. Pharmacology
Subject Terms:	microRNA, long noncoding RNA, circular RNA, retinopathy of prematurity, retinal vascular disease, noncoding RNA, Therapeutics. Pharmacology, RM1-950
More Details:	Retinopathy of prematurity (ROP), a vascular disease characterized by abnormal vessel development in the retina, has become a primary cause of blindness in children around the world. ROP can be developed during two different phases: vessel loss and vessel proliferation. Once preterm infants with immature retinal vessel growth are exposed to high level of oxygen inside the incubator, vessel loss can occur. When infants are exposed to room air, they may experience the proliferation of vessels in the retina. Although multiple factors are reported to be involved in the pathogenesis of ROP, including vaso-endothelial growth factors (VEGFs) and hypoxia-inducible factors, the pathogenesis of ROP is not completely understood. Although laser therapy and pharmacologic agents, such as anti-VEGF agents, have been commonly used to treat ROP, the incidence of ROP is rapidly rising. Given that current therapies can be invasive and long-term effects are not fully known, the search for novel therapeutic targets with less destructive properties needs to be considered. Within the last decade, the field of noncoding RNA therapy has shown potential as next-generation therapy to treat diverse diseases. In this review, we introduce various noncoding RNAs regulating ROP and discuss their role as potential therapeutic targets in ROP.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1663-9812
Relation:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1033341/full; https://doaj.org/toc/1663-9812
DOI:	10.3389/fphar.2022.1033341
Access URL:	https://doaj.org/article/d889086d7bcd4d37af67c4e37b77d88c
Accession Number:	edsdoj.889086d7bcd4d37af67c4e37b77d88c
Database:	Directory of Open Access Journals

FullText	Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=16639812&ISBN=&volume=13&issue=&date=20221001&spage=&pages=&title=Frontiers in Pharmacology&atitle=Noncoding%20RNAs%20as%20a%20novel%20approach%20to%20target%20retinopathy%20of%20prematurity&aulast=Hyunjong%20Kim&id=DOI:10.3389/fphar.2022.1033341 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries – Url: https://doaj.org/article/d889086d7bcd4d37af67c4e37b77d88c Name: EDS - DOAJ (s8985755) Category: fullText Text: View record from DOAJ MouseOverText: View record from DOAJ
Header	DbId: edsdoj DbLabel: Directory of Open Access Journals An: edsdoj.889086d7bcd4d37af67c4e37b77d88c RelevancyScore: 953 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 953.466857910156
IllustrationInfo
Items	– Name: Title Label: Title Group: Ti Data: Noncoding RNAs as a novel approach to target retinopathy of prematurity – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Hyunjong+Kim%22">Hyunjong Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Jaesub+Kim%22">Jaesub Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Juhee+Ryu%22">Juhee Ryu</searchLink> – Name: TitleSource Label: Source Group: Src Data: Frontiers in Pharmacology, Vol 13 (2022) – Name: Publisher Label: Publisher Information Group: PubInfo Data: Frontiers Media S.A., 2022. – Name: DatePubCY Label: Publication Year Group: Date Data: 2022 – Name: Subset Label: Collection Group: HoldingsInfo Data: LCC:Therapeutics. Pharmacology – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22microRNA%22">microRNA</searchLink><br /><searchLink fieldCode="DE" term="%22long+noncoding+RNA%22">long noncoding RNA</searchLink><br /><searchLink fieldCode="DE" term="%22circular+RNA%22">circular RNA</searchLink><br /><searchLink fieldCode="DE" term="%22retinopathy+of+prematurity%22">retinopathy of prematurity</searchLink><br /><searchLink fieldCode="DE" term="%22retinal+vascular+disease%22">retinal vascular disease</searchLink><br /><searchLink fieldCode="DE" term="%22noncoding+RNA%22">noncoding RNA</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%2E+Pharmacology%22">Therapeutics. Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22RM1-950%22">RM1-950</searchLink> – Name: Abstract Label: Description Group: Ab Data: Retinopathy of prematurity (ROP), a vascular disease characterized by abnormal vessel development in the retina, has become a primary cause of blindness in children around the world. ROP can be developed during two different phases: vessel loss and vessel proliferation. Once preterm infants with immature retinal vessel growth are exposed to high level of oxygen inside the incubator, vessel loss can occur. When infants are exposed to room air, they may experience the proliferation of vessels in the retina. Although multiple factors are reported to be involved in the pathogenesis of ROP, including vaso-endothelial growth factors (VEGFs) and hypoxia-inducible factors, the pathogenesis of ROP is not completely understood. Although laser therapy and pharmacologic agents, such as anti-VEGF agents, have been commonly used to treat ROP, the incidence of ROP is rapidly rising. Given that current therapies can be invasive and long-term effects are not fully known, the search for novel therapeutic targets with less destructive properties needs to be considered. Within the last decade, the field of noncoding RNA therapy has shown potential as next-generation therapy to treat diverse diseases. In this review, we introduce various noncoding RNAs regulating ROP and discuss their role as potential therapeutic targets in ROP. – Name: TypeDocument Label: Document Type Group: TypDoc Data: article – Name: Format Label: File Description Group: SrcInfo Data: electronic resource – Name: Language Label: Language Group: Lang Data: English – Name: ISSN Label: ISSN Group: ISSN Data: 1663-9812 – Name: NoteTitleSource Label: Relation Group: SrcInfo Data: https://www.frontiersin.org/articles/10.3389/fphar.2022.1033341/full; https://doaj.org/toc/1663-9812 – Name: DOI Label: DOI Group: ID Data: 10.3389/fphar.2022.1033341 – Name: URL Label: Access URL Group: URL Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/d889086d7bcd4d37af67c4e37b77d88c" linkWindow="_blank">https://doaj.org/article/d889086d7bcd4d37af67c4e37b77d88c</link> – Name: AN Label: Accession Number Group: ID Data: edsdoj.889086d7bcd4d37af67c4e37b77d88c
PLink	https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.889086d7bcd4d37af67c4e37b77d88c
RecordInfo	BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fphar.2022.1033341 Languages: – Text: English Subjects: – SubjectFull: microRNA Type: general – SubjectFull: long noncoding RNA Type: general – SubjectFull: circular RNA Type: general – SubjectFull: retinopathy of prematurity Type: general – SubjectFull: retinal vascular disease Type: general – SubjectFull: noncoding RNA Type: general – SubjectFull: Therapeutics. Pharmacology Type: general – SubjectFull: RM1-950 Type: general Titles: – TitleFull: Noncoding RNAs as a novel approach to target retinopathy of prematurity Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hyunjong Kim – PersonEntity: Name: NameFull: Jaesub Kim – PersonEntity: Name: NameFull: Juhee Ryu IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 16639812 Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in Pharmacology Type: main
ResultId	1